Ezetimibe added to statin therapy (EASY study) - an evaluation by Australian general practitioners

Area of Science:

• Cardiology
• Pharmacology
• General Practice

Background:

• Assessing the impact of adding ezetimibe to statin monotherapy.
• Evaluating low density lipoprotein cholesterol (LDL-C) goal attainment under Pharmaceutical Benefits Scheme (PBS) guidelines.
• Focusing on a general practice setting in Australia.

Purpose of the Study:

• To estimate changes in LDL-C levels.
• To determine the proportion of patients reaching a goal LDL-C of <2.5 mmol/L.
• To assess ezetimibe's effectiveness when added to statin therapy.

Main Methods:

• Included patients with coronary heart disease or diabetes mellitus eligible for ezetimibe under PBS.
• Administered ezetimibe 10 mg/day alongside existing statin therapy for 6 weeks.
• Analyzed a per-protocol subpopulation of 95 patients for effectiveness.

Main Results:

• Achieved a 29% reduction in LDL-C (95% CI, 25-34%).
• Reached the goal LDL-C <2.5 mmol/L in 70% of patients (95% CI, 59-79%).
• Reported 6 patient withdrawals due to adverse events.

Conclusions:

• Ezetimibe added to statin therapy effectively reduced LDL-C in Australian general practice.
• Goal LDL-C attainment was high, consistent with clinical trial findings.
• The study supports ezetimibe's role in managing hyperlipidemia in primary care.